BEATW — HeartBeam, Inc.

HeartBeam, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: For Q4 2025, HeartBeam reported a net loss of $5.3 million, or $0.15 per share, consistent with expectations. For the full year, the net loss was $21 million, or $0.62 per share.
• Operating Cash Flow: Net cash used in operating activities was less than $14 million for the full year and $2.9 million for Q4, reflecting a 30% decrease compared to the same quarter last year.
• Cash Position: As of December 31, 2025, cash and cash equivalents totaled $4.4 million. The company has access to capital markets and various funding vehicles.

2. Strategic Updates and Business Highlights

• FDA Clearances: HeartBeam received FDA 510(k) clearance for its 12-lead synthesis software for arrhythmia assessment, enabling a limited commercial launch. This follows a successful engagement with the FDA that overturned a prior NSE letter.
• Product Development: The company unveiled a working prototype of a 12-lead ECG patch, aiming to disrupt the $2 billion ambulatory cardiac monitoring market.
• Commercial Launch Strategy: The initial focus is on concierge and preventive cardiology practices, targeting high-net-worth individuals. The expected price per patient is $500 to $1,000 annually.
• Clinical Studies: Enrollment has begun for the ALIGN ACS study in Europe, comparing the HeartBeam ECG to standard 12-lead ECGs for heart attack detection.

3. Forward Guidance and Outlook

• 2026 Expectations: Operating cash outflows are projected to remain around $14 million, with incremental investments for commercialization adding $3 million to $5 million, leading to total cash outflows of approximately $17 million to $19 million.
• Growth Plans: The company aims to validate its business model in the concierge market before scaling to a broader patient-pay segment. They anticipate achieving cash flow breakeven with approximately 30,000 patients.

4. Bad News, Challenges, or Points of Concern

• Regulatory Uncertainty: While the patch is likely to follow a 510(k) pathway, the regulatory path for heart attack detection remains uncertain, which could delay commercialization.
• Market Competition: The company faces competition in the telehealth and cardiac monitoring space, necessitating strong differentiation of its technology.
• Dependence on Initial Accounts: The strategy relies heavily on securing a limited number of anchor accounts for initial validation, which could pose risks if adoption does not meet expectations.

5. Notable Q&A Insights

• Clinical Study Timelines: The ALIGN ACS pilot study is expected to complete enrollment by the end of Q3 2026, which will inform a pivotal study needed for FDA approval.
• Commercialization Focus: The initial strategy is to engage a small number of concierge practices to prove the model before expanding to a larger market.
• AI Collaboration: A strategic partnership with Mount Sinai aims to develop advanced AI algorithms for the HeartBeam system, enhancing its clinical utility.
• Sales Strategy: The company plans to expand its commercial team in 2026 as it scales, focusing on efficient implementation and deep adoption within targeted accounts.

Overall, HeartBeam, Inc. is positioned for growth with its innovative ECG technology and strategic focus on high-value markets, although it must navigate regulatory challenges and competitive pressures.